Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

New AACR Cancer Progress Report Spotlights Notable Gains, Ongoing Challenges in Research

September 17th 2025

AACR published its annual Cancer Progress Report, outlining advances in cancer treatment and areas for future improvement.

Ligufalimab Nets FDA Orphan Drug Designation in AML

September 16th 2025

Ligufalimab has been granted orphan drug designation by the FDA for the treatment of patients with AML.

Second-Line Axi-Cel and Liso-Cel Lead as Standards of Care in LBCL

September 11th 2025

Supriya Gupta, MD, discussed the utility of axi-cel and liso-cel in real-world settings as second-line treatment in large B-cell lymphoma.

Orelabrutinib Receives Approval in Singapore for Marginal Zone Lymphoma

September 11th 2025

Orelabrutinib has been approved as a treatment option for patients with marginal zone lymphoma in Singapore.

SOHO Spotlight: Hematologists Share Practice-Informing Insights From the 2025 Annual Meeting

September 10th 2025

Hematology experts highlight the MDS, lymphoma, and myeloma data they were most excited to see at the 2025 SOHO Annual Meeting.

Yale Study: Potential Treatment Pathway Found for Rare and Aggressive Leukemia

September 9th 2025

A Yale study published identified the mechanism underlying the relationship between the development of AMKL and a specific genetic alteration that occurs.

Highlighting Key ALL Updates and Data From EHA 2025

September 8th 2025

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss key data in acute lymphoblastic leukemia presented at the 2025 EHA Congress.

Early Data for Subcutaneous Blinatumomab in R/R ALL

September 8th 2025

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss data for subcutaneous in relapsed/refractory acute lymphoblastic leukemia.

Five Under 5: Top Oncology Videos for the Week of 8/31

September 7th 2025

The top 5 OncLive videos of the week cover insights in sarcoma, colorectal cancer, acute lymphoblastic leukemia, renal cell carcinoma.

Mosunetuzumab Plus Polatuzumab Vedotin Triples Median PFS in Transplant-Ineligible LBCL

September 6th 2025

A chemotherapy-free regimen of mosunetuzumab and polatuzumab vedotin improved PFS and response rates vs R-GemOx in relapsed/refractory LBCL.

Loncastuximab Tesirine Plus Glofitamab Shows Early Safety and Efficacy in R/R DLBCL

September 6th 2025

Loncastuximab tesirine plus glofitamab demonstrated early promise in patients with relapsed or refractory large B-cell lymphoma.

Dr Issa on Testing for NPM1 or KMT2A Alterations in AML

September 6th 2025

Ghayas C. Issa, MD, MS, discusses the optimal timing of and approaches to genetic testing for NPM1 and KMT2A alterations in AML.

Mosunetuzumab Demonstrates High Response Rates in Treatment-Naive MZL

September 5th 2025

Frontline treatment with mosunetuzumab showed high antitumor activity in patients with marginal zone lymphoma regardless of risk status.

FDA Grants Fast Track Designation to CER-1236 in Acute Myeloid Leukemia

September 5th 2025

CER-1236 has received fast track designation from the FDA for the treatment of patients with acute myeloid leukemia.

Ziftomenib With 7+3 Shows Early Promise in Newly Diagnosed NPM1-Mutated/KMT2A-Rearranged AML

September 4th 2025

The combination of ziftomenib and cytarabine/daunorubicin showed a manageable safety profile with early efficacy in NPM1-mutated and KMT2A-rearranged AML.

Peak CAR T-Cell Expansion Associated With Reduced Relapse Risk Following Brexu-Cel Consolidation in B-ALL

September 4th 2025

Favorable long-term outcomes were reported with brexu-cel in patients with B-ALL and low disease burden who achieved peak CAR T-cell expansion.

Meta-Analysis Highlights Efficacy, Safety Benefits With Asciminib in Chronic Myeloid Leukemia

September 4th 2025

Findings from a meta-analysis associated asciminib with improved efficacy and safety vs other TKIs in chronic myeloid leukemia.

Olutasidenib Monotherapy Yields Responses in Primary Refractory IDH1-Mutant AML

September 4th 2025

A post hoc analysis demonstrated the efficacy of olutasidenib monotherapy in primary refractory patients with IDH1-mutant AML.

Dr Cortes on the Evolving Treatment Paradigm for Leukemia and Lymphoma

September 3rd 2025

Jorge Cortes, MD, discusses the state of the leukemia and lymphoma treatment paradigms in 2025 in recognition of Leukemia and Lymphoma Awareness Month

Dr Aldoss on MRD Negativity Outcomes With Ponatinib vs Imatinib in Newly Diagnosed Ph+ ALL

September 3rd 2025

Ibrahim T. Aldoss, MD, discusses MRD negativity outcomes with ponatinib vs imatinib in newly diagnosed Philadelphia chromosome–positive ALL.